The objectives of this training manual are to: 1) Understand the role of Family Planning in reducing maternal and infant morbidity and mortality; 2) Describe the organization, management and record keeping of Postpartum Family Planning Service; and 3) Transfer learning from the training to the work site, through an action plan, support and supervision.

Eclampsia remains an important cause of maternal mortality throughout the world. Although it has long been standard practice to use an anticonvulsant for the care of women with eclampsia, the choice .of agent has been controversial for more than 70 years. This situation changed recently with the publication of the Collaborative Eclampsia Trial, involving nearly 1700 women with eclampsia'. In this study, roughly half the women were randomized to receive either magnesium sulphate or diazepam, and the other half were randomized to either magnesium sulphate or phenytoin. In the diazepam arm of the trial, women allocated magnesium sulphate had a 52 YO lower risk of recurrent convulsions (95 YO CI 64 % to 37 %) than those on diazepam. In the phenytoin arm, women allocated magnesium had a 67 YO lower risk of recurrent convulsions (95 YO CI 79 YO to 47%) than those on phenytoin. There is now, for the first time, compelling evidence in favor of magnesium sulphate, rather than diazepam or phenytoin, for the treatment of women with eclampsia.

The presentation delves into the clinical problems of severe pre-eclampsia and how to improve the cost effectiveness of the treatment.

This presentation shows how the Pre-Eclampsia foundation is dedicated to reducing maternal and infant illness and death through research public awareness, professional education, and patient education and support.

This prospective study was conducted at Dhaka Medical College and Hospital, Bangladesh. The objective was to identify the time required to control high blood pressure levels in obstetric patients by injection of hydralazine in a bolus intravenous dose vs continuous drip. Seventy-seven patients with eclampsia and hypertensive emergencies comprised the target population. Patients were managed either by hydralazine drip in normal saline (existing official protocol, n = 33) or hydralazine bolus injection (as experiment, n = 44) until diastolic blood pressure fell to 90-95 mmHg. Results were compared. Student's t-test was done for statistical significance, and a P value of < .05 was considered as significant.The groups were similar with respect to maternal age and their mean systolic and diastolic blood pressure at the time of enrollment. Patients who received bolus injection required less time to achieve the therapeutic goal (65,23 +/- 23,38 minutes) than continuous drip (186,36 +/- 79,77 minutes; P < .001). The experimental group also required significantly lower doses (6,68 +/- 1,66 mg) in comparison to that required by control group (20,07 +/- 11,38 mg; P < .001). There was no overshoot hypotension in either group.The data suggest that hydralazine bolus dose is equally safe and more effective than continuous drip in the management of hypertensive emergencies in pregnancy.

The presentation covers the pre-eclampsia induction techniques and how the timing of delivery affects the birth.

This presentation explains the detection of pre-eclampsia and why early administration of Magnesium Sulphate can help prevent convulsion and other convulsions.

This presentation explains not only the how pre-eclampsia was detected historically, but also in present day.  Professor Senevirante also explores the healthcare organizational structure in Sri Lanka.

This presentation explains the experience of calcium supplementation in Latin American Pre-Eclampsia/Eclampsia women.

The presentation explains what antihypertensive is and why it's important to use them especially in rural and remote settings.

This presentation concentrates on the strategies used to prevent preeclampsia.

This presentation proposes a new comprehensive approach for preventing mortality from Pre-Eclampsia and Eclampsia in Nepal.

This document aims to observe whether the pregnancy can be safely continued for a reasonable period to gain fetal maturity in cases of eclampsia and severe pre-eclampsia.

This presentation is meant to review women’s perspectives of PE/E, including misconceptions, fears, their acceptance or otherwise of treatment and to address the challenges of over-medicalization in PE/E

This presentation aims to identify scaling-up strategies and evaluation frameworks that are both scientifically sound and acceptable for policy makers and research funders.

This article explains why low cost and effective drugs, such as magnesium sulphate, need to be included in initiatives to improve access to essential medicines in Africa and and why they are not there already.

This presentation reviews the efforts to improve the management of preeclampsia and eclampsia (PE/E) in Burkina Faso and to review some of the challenges and successes in managing with PE/E.

This descriptive study, conducted at Dhaka Medical College and Hospital, Bangladesh, includes 2956 consecutive eclamptic patients who were admitted between 1998 and 2000 and evaluates their outcomes after treatment with magnesium sulfate. Although magnesium sulfate controls convulsion efficiently, death from eclampsia remains high in our country. Thus, a second purpose of this study was to identify additional factors responsible for death from eclampsia. Among 32 999 obstetric patients admitted to the hospital during the years 1998 to 2000, 2956 were eclamptic, yielding an incidence of 9%. The antepartum/intrapartum and postpartum incidences of eclampsia were 80% and 20%, respectively. Among the patients with eclampsia, 79% had good prognosis without any added complication except convulsion, and 21% had other complications. For the period 1998 to 2000, the rate of maternal death from eclampsia was 8,6%, which was lower than that of the immediate past year (1997) for which the mortality was 16%.  Changing the protocol from diazepam to magnesium sulfate for control of convulsion significantly reduced the incidence of death. But reduction of the risk of death was difficult when patients had developed complications. Most of the patients in the group who had complications died (98%); these complications developed as a result of a delayed decision for treatment. Therefore, efforts should be directed at developing awareness to receive treatment at an appropriate time to prevent the development of eclampsia and to reduce the mortality from eclampsia and its complications.

Anticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve outcome. Evidence supported magnesium sulphate as the drug to evaluate.

This presentation examines the different talking points which were brought up during the meeting of a technical working group on Pre-Eclampsia and Eclampsia.  The use of Magnesium sulphate and when/how it is appropriate to implement it.